Rhomboid Intercostal and Subserratus / Paravertebral Block
Launched by ULUDAG UNIVERSITY · Feb 9, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two types of anesthesia techniques to help manage pain after a specific type of surgery called video-assisted thoracoscopic surgery (VATS). Pain control after this surgery is very important because it can affect recovery and make patients feel stressed or anxious. The two methods being compared are the paravertebral block (PVB) and the Rhomboid Intercostal and Subserratus block (RISS), both of which aim to reduce pain after surgery.
To participate in this trial, individuals must be between the ages of 18 and 80 and scheduled to undergo VATS. They should be in good health according to the American Society of Anesthesiologists (ASA) class I or II, which means they have minimal or no health issues. However, those with certain conditions, such as allergies to the anesthetic, bleeding disorders, or severe heart or kidney problems, will not be eligible. Participants can expect to receive one of the two pain control techniques and be monitored for their effectiveness in reducing pain after surgery. This study is not yet recruiting participants, but it aims to provide valuable information on improving pain management for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Planned for VATS
- • American Society of Anesthesiologists (ASA) class I and II
- • Patients aged between 18-80
- Exclusion Criteria:
- • Contraindications to local anesthetic allergy or bupivacaine
- • Known or suspected coagulopathy
- • Injection site infection
- • History of thoracic surgery
- • Severe neurological or psychiatric disorder
- • Severe cardiovascular disease
- • Liver failure
- • Renal failure (glomerular filtration rate \<15 ml/min/1.73 m2)
- • Chronic opioid use
About Uludag University
Uludağ University is a leading academic institution located in Bursa, Turkey, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, Uludağ University leverages its extensive expertise and resources to facilitate innovative research initiatives aimed at improving healthcare outcomes. The university's collaborative approach fosters partnerships with healthcare professionals, researchers, and industry stakeholders, ensuring rigorous adherence to ethical standards and regulatory guidelines. Through its clinical trials, Uludağ University aims to contribute significantly to the scientific community and enhance the understanding of various medical conditions and treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bursa, , Turkey
Patients applied
Trial Officials
SEDA CANSABUNCU
Principal Investigator
Uludag University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported